News and Trends 23 Jul 2018 Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent organ transplant rejections and treat autoimmune disease. Sangamo, based in California, is known for bringing the first in-vivo gene therapy to the market. The company entered into an agreement to purchase TxCell for €72M. Sangamo plans to combine its zinc […] July 23, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2018 Kite Partners with Dutch Biotech to Develop a New Form of CAR-T Therapy Kite will support Gadeta in the development of a new type of CAR-T therapy that could be more effective in solid tumors. Approved just last year, CAR-T cell therapy is offering hope to patients with severe forms of blood cancer. The developer of one of only two CAR-T therapies currently in the market, Kite, has […] July 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2018 Next-Generation CAR-T Company Raises €130M on NASDAQ IPO London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a next generation of CAR-T cell therapy for cancer. Founded in 2014 as a spin-out from University College London, Autolus has been taking great strides to develop its CAR-T technology. In less than four years, the company managed to raise nearly €150M […] June 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2018 French Biotech Develops a New Generation of Safer CAR-T Cells Cellectis is developing a new type of chimeric antigen receptor that could improve the production and safety of CAR-T cell therapies generated from both patient and donor cells. Cellectis, a French biotech focused on developing CAR-T therapies from donor cells, has published a study in the journal Scientific Reports describing technological advances that could improve the […] June 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 13 Jun 2018 CAR-T Brings Hope for Cancer Patients, But Challenges Lie Ahead CAR-T cell therapy has been able to effectively treat cancer in some patients for whom all other treatment options were exhausted. However, the technology still has a long road ahead before becoming a widespread treatment option. Philip spoke to Christian Homsy, CEO of Celyad, at our Refresh Meetup in Brussels about the challenges CAR-T cell […] June 13, 2018 - 5 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race Update (23/05/2018): Investors have fully subscribed Celyad’s global offering of shares on NASDAQ and Euronext Paris, making the company raise a total of $54.4M (€46M) to support the development of its CAR-T technology. 18/05/2018 Celyad has raised €40M ($47M) in a global offering, which could help the company keep up with large competitors amidst recent large […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2018 Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation of safer CAR-T therapies against multiple types of tumors as well as viral infections such as HIV. The Scottish biotech TC Biopharm will be working with its new partner Scotia Biologics on the development of CAR-T therapy candidates against neuroblastoma, […] May 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Apr 2018 The First CAR-T Therapy Is Not Living Up to Commercial Expectations Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […] April 23, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2018 “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“ Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. At the AACR meeting in Chicago this week, Celyad has presented preliminary data from three of its ongoing Phase 1 clinical trials with a new […] April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2018 French CAR-T Developer Raises $164M Despite a Challenging Road Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in clinical trials, despite having mixed results in the technology’s development up until now. Cellectis, based in Paris, has closed a follow-on offering on NASDAQ, raising a total of around $164M (€132M). The funding will be used to further continue clinical development […] April 11, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 13 Mar 2018 The Most Important Battle in Gene Editing: CRISPR versus TALEN Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since the gene editing technology first entered the spotlight in 2012 with the promise of revolutionizing gene editing, it has made headlines as the subject of a furious […] March 13, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Interview 19 Feb 2018 Taking CAR-T Cells Beyond Cancer: A New Therapy for Autoimmune Disease CAR-T cells are all the rage as the latest treatment for cancer. But what if we could apply this same technology to treat autoimmune disease? Curious to learn whether this new technology could revolutionize yet another field of medicine, I talked to Stephane Boissel, CEO of TxCell, to discuss the future of the field and his […] February 19, 2018 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email